Program

Friday, September 16th 2016

11.00 - 12.00 pm

Treffen der DCLLSG Strategiekommission

12.00 - 1.00 pm

Lunch

1.00 - 3.30 pm

Young Investigators’ Meeting

1.00 - 3.00 pm

Arbeitstreffen der DCLLSG

Vorsitz: M-J Eckart, U Jäger

1.00 - 1.10 pm

Begrüßung

M Hallek

1.10 - 1.30 pm

CLL2-BCG-Protokoll

P Cramer

1.30 - 1.50 pm

CLLRUmbrella-Protokoll

B Eichhorst

1.50 - 2.10 pm

CLLR3-Protokoll

C-M Wendtner

2.10 - 2.30 pm

CLLTX1-Protokoll

N Pflug, M von Bergwelt

2.30 - 3.00 pm

CLL-Studien – Quo Vadis?

Podiumsdiskussion
M-J Eckart, B Eichhorst, M Hallek, M Hensel, C-M Wendtner

Schlusswort
M Hallek

3.00 - 3.30 pm

Coffee & Tea

3.30 - 6.30 pm

Workshop GCLLSG – What’s in the pipeline?

Chair: B Eichhorst, M Kneba

3.30 - 3.40 pm

Welcome

M Hallek

3.40 - 4.00 pm

CLLM1-Protocol

A Fink

4.00 - 4.20 pm

CLL2-BIG-Protocol

J von Tresckow

4.20 - 4.40 pm

CLL2-BAG-Protocol

P Cramer

4.40 - 5.00 pm

CLL14-Protocol

K Fischer

5.00 - 5.20 pm

CLL12-Protocol

P Langerbeins

5.20 - 5.40 pm

CLL13-Protocol

J von Tresckow

5.40 - 6.00 pm

GIVe-Protocol

S Stilgenbauer

6.00 - 6.20 pm

GCLLSG Registry

A Fink

6.20 - 6.30 pm

Closing remarks

M Hallek

6.30 - 7.30 pm

Dinner

7.30 - 8.00 pm

Satellite Symposium I

Gilead Sciences GmbH

8.00 - 9.00 pm

Keynote Lecture

J Gribben, London

Saturday, September 17th 2016

8.30 - 9.30 am

Session I: Immune evasion in CLL

Chair: F Caligaris-Cappio, T Kipps

Epigenetic and Genetics: novel insights
C Croce, Columbus

Microenvironment
P Ghia, Milan

Games of Clones
D Landau, New York

Development of Richter´s Transformation
D Rossi, Bellinzona

9.30 - 10.30 am

Session II: Evolution of prognosis in CLL

Chair: N Kay, S Stilgenbauer

Classic prognostic markers: now and then
E Montserrat, Barcelona

Back to the future: CLL-IPI
J Bahlo, Cologne

Methods: FISH, Karyotyping, NGS
A Schuh, Oxford

10.30 - 11.00 am

Coffee & Tea

11.00 - 11.45 am

Satellite Symposium II

AbbVie Deutschland GmbH & Co. KG

11.45 - 12.30 pm

Satellite Symposium III

Roche Pharma AG

12.30 - 2.00 pm

Lunch

2.00 - 3.30 pm

Session III: Therapy of CLL

Chair: D Catovsky, K Fischer

Therapy of previously untreated patients
B Eichhorst, Cologne

Therapy of previously treated patients
C Niemann, Copenhagen

New compounds
J Woyach, Columbus

Allo SCTx in the era of kinase inhibitors
J Gribben, London

3.30 - 4.00 pm

Coffee & Tea

4.00 - 4.45 pm

Satellite Symposium IV

Janssen-Cilag GmbH

4.45 - 5.45 pm

Session IV: Clinical approaches in CLL management

Chair: S O’Brien, M Kneba

House of CARTs: Update
H Abken, Cologne

MRD: roles & responsibilities
A Rawstron, Leeds

Checkpoint inhibition
A Ramsay, London

5.45 - 7.00 pm

Session V: Challenges

Chair: M Keating, T Robak

Resistance to new compounds
A Kater, Amsterdam

Using the TME in CLL as a therapeutic target
F Caligaris-Cappio, Milan

Richter´s Transformation under kinase Inhibitors: a new challenge?
M Keating, Houston

Inhibitors: a new challenge?

Best of YIM
M Davids, Boston

iwCLL Core Group: update guidelines
M Hallek, Cologne

7.00 - 7.15 pm

Discussion

8.00 pm

Dinner on the occasion of the 20th anniversary of the German CLL Study Group

Sunday, September 18th 2016

8.00 - 12.00 pm

Departure